Skip to main content
OPKO Health Inc. logo

OPKO Health Inc. — Investor Relations & Filings

Ticker · OPK ISIN · US68375N1037 LEI · 529900A4S2D4OGOJLL02 TA Human health and social work activities
Open in API
Filings indexed 3,780 across all filing types
Latest filing 2025-07-31 Earnings Release
Country US United States of America
Listing TA OPK

About OPKO Health Inc.

https://www.opko.com

OPKO Health, Inc. is a fully-integrated healthcare company operating in both pharmaceuticals and diagnostics. Its pharmaceutical division develops and commercializes novel therapies for serious diseases. Key marketed products include NGENLA™, a long-acting treatment for pediatric growth hormone deficiency partnered with Pfizer, and RAYALDEE®. The company's research focuses on advancing multispecific therapies for cancers and infectious diseases. Through its subsidiary, BioReference Laboratories, OPKO operates one of the largest full-service clinical reference laboratories in the U.S., providing comprehensive diagnostic testing services to millions of patients annually.

Recent filings

Filing Released Lang Actions
Immediate Report
Earnings Release Classification · 100% confidence The document is a press release titled 'OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results'. It provides a summary of quarterly financial performance, business highlights, and forward-looking statements. It is not a full 10-Q or 10-K report, but rather the initial announcement of quarterly results, which fits the definition of an Earnings Release (ER). Q2 2025
2025-07-31 English
Immediate Report
Report Publication Announcement Classification · 100% confidence The document is a short regulatory filing (1871 characters) that explicitly states 'Attached hereto is a report on OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results' and provides a filename for the attachment. According to the 'Menu vs Meal' rule, this is an announcement of a report rather than the report itself, making it a Report Publication Announcement (RPA).
2025-07-31 English
Immediate Report
Report Publication Announcement Classification · 100% confidence The document is a short announcement (2184 characters) informing the public and investors about the upcoming release of financial results for the second quarter of 2025. It provides the date of the earnings release and details for the subsequent conference call. According to the 'Menu vs Meal' rule, since this is an announcement of a future report rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2025-07-26 English
Immediate Report
Report Publication Announcement Classification · 100% confidence The document is a short regulatory filing (under 2,000 characters) that serves as an announcement regarding the upcoming release of financial results. It explicitly states 'Attached hereto is a report on OPKO Health to Report Second Quarter 2025 Financial Results on July 31' and provides a filename for the attachment. Following the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA) rather than the financial report itself.
2025-07-26 English
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
Regulatory Filings Classification · 100% confidence The document is a press release dated July 8, 2025, announcing that an abstract regarding a drug development program between OPKO Health and Entera Bio has been selected for a poster presentation at the ESPEN Congress. This type of announcement, detailing scientific progress, clinical trial updates, or presentation schedules, is characteristic of communications aimed at investors and the scientific community, but it is not a formal regulatory filing like a 10-K, 10-Q (IR), or a formal Earnings Release (ER). It is a general corporate announcement regarding scientific data presentation. Since it doesn't fit the specific categories like AGM-R, 10-K, ER, IR, or CT, and it is a specific corporate update, the most appropriate classification is Regulatory Filings (RNS) as a general announcement, or potentially Investor Presentation (IP) if it were the presentation itself, but here it is an announcement *about* a presentation. Given the context of a press release announcing scientific data presentation, RNS serves as the best general regulatory/corporate announcement category when a more specific one (like ER or CT) is not applicable. However, since it is a detailed update on product development and scientific findings, it strongly aligns with investor communication materials. Given the options, and recognizing this is a press release detailing scientific progress rather than a formal financial report or a call transcript, RNS (Regulatory Filings/General Announcement) is the safest fallback, although Investor Presentation (IP) might also be considered if the content were more strategic/forward-looking presentation material. Since it is a press release announcing an abstract selection, RNS is the most fitting general category for non-standard corporate news.
2025-07-08 English
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
Report Publication Announcement Classification · 98% confidence The document is a short filing (1829 chars) submitted to the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). It explicitly states, "Attached hereto is a report on *����� �� GLP2 ������ �- SBS ���� ������ ���� ���� ESPEN2025.*" and references a PDF file. This structure—a brief announcement stating that a specific report is attached or published, rather than containing the full content of the report itself—fits the definition of a Report Publication Announcement (RPA). It is not a comprehensive report like a 10-K or IR, nor is it a general regulatory filing (RNS) since a more specific category (RPA) applies based on the 'Menu vs Meal' rule.
2025-07-08 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.